Second-line chemotherapy for non-small cell lung cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 435-442

  Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Combination therapy; Non small cell lung cancer; Response rare; Second line chemotherapy; Single agent therapy

Indexed keywords

4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CELECOXIB; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ERYTHROPOIETIN; FLAVOPIRIDOL; FOLIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GW 3191; IFOSFAMIDE; IRINOTECAN; LONAFARNIB; NAVELBINE; OBLIMERSEN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PSC 341; TOPOTECAN; UNCLASSIFIED DRUG; VINCA ALKALOID; VINDESINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; RASH; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0042010018     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.435     Document Type: Review

References (28)

1. Shepherd FA, Carney DN. Treatment of non-small cell lung cancer: chemotherapy. In: International Association for the Treatment of Lung Cancer: Textbook of Lung Cancer. Hansen HH (Ed). Martin Dunitz Ltd., London, UK, 213-242 (2000).
2. Schiller JH. Chemotherapy for advanced non-small cell lung cancer. In: Lung Cancer Principles and Practice, second edition. Pass H, Mitchell J, Johnson D, Turrissi A, Minna J (Eds). Lippincott Williams & Wilkins, PA, USA, 889-902 (2000).
3. Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 899-909(1995).
4. Fossella FV. Second-line chemotherapy for non-small cell lung cancer. In: Lung Cancer Principles and Practice, second edition. Pass H, Mitchell J, Johnson D, Turrissi A, Minna J (Eds). Lippincott Williams & Wilkins, PA, USA, 902-909 (2000).
5. American Society of Clinical Oncology treatment guidelines for unresectable non-small cell lung cancer. J. Clin. Oncol. 15, 2996-3019 (1997).
6. Belani CP. Single agents in the second-line treatment of non-small cell lung cancer. Semin. Oncol. 25(Suppl. 8), 10-14 (1998).
7. Fossella FV. Second-line chemotherapy for non-small cell lung cancer. In: Lung Cancer Principles and Practice, second edition. Pass H, Mitchell J, Johnson D, Turrissi A, Minna J (Eds). Lippincott Williams & Wilkins, PA, USA, 903-910 (2000).
8. Shepherd F, Dancey J, Ramlau R et al. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin. Oncol 18, 2095-2103 (2000).
9. Fossella FV, DeVore R, Kerr R et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 18, 2354-2362 (2000).
10. 2/3 weeks in a second-line treatment of locally advanced or metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 19, 501a (2000) (Abstract 1959).
11. Hainsworth JD, Burris HA III, Earland JD et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16, 2164-2168(1998).
12. Hainsworth JD, Burris HA III, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J. Clin. Oncol. 19, 3500-3505 (2001).
13. Huisman C, Smit ES, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer. A review. J. Clin. Oncol. 18, 3722-3730 (2000).
14. Garfield DH, Dakhil SR, Whittaker TL et al. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC) Proc. Am. Soc. Clin. Oncol. 17, 484a (1998) (Abstract 1863).
15. von Pawel J, Shepherd F, Gatzmeier U et al. Randomized Phase II study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine versus gemcitabine plus placebo in second-line non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21, 310a (2002) (Abstract 1239).
16. Smit ES, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus P. Alimta (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann. Oncol. 14, 455-460 (2003).
17. Hanna N, Shepherd F, Rosell R, Pereira J et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously treated with chemotherapy. Proc. Am. Soc. Clin. Oncol. 22, 622 (2003) (Abstract 2503).
18. Perez-Soler R, Fossella FV, Glisson BF et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14, 503-513 (1996).
19. Georgoulias V. Chemotherapy for advanced non-small cell lung cancer. Proc. Int. Congress Anticancer Treat. 8-9 (2002).
20. Hainsworth JD, Burris HA III, Billings FT III, Bradof JE, Baker M, Greco FA. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced non-small cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network. Cancer 92, 2391-2398 (2001).
21. Fukuoka M, Yano S, Giaccone G et al. Final results from a Phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. Am. Son Clin. Oncol 21, 2989 (2002) (Abstract 1188).
22. Kris MG, Natale RB, Herbst RS et al. A Phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failedplatinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21, 2929 (2002) (Abstract 1166).
23. Giaccone G, Johnson DH, Manegold C et al. A Phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann. Oncol. 13(5), 2 (2002) (Abstract 4).
24. Johnson DH, Herbst R, Giaccone G et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a Phase III clinical trial (INTACT 2). Ann. Oncol. 13(5), 127 (2002) (Abstract 468).
25. Perez-Soler R, Chachoua A, Huberman M et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 210a (2001) (Abstract 1235).
26. Johnson D. Highlights of lung cancer research: introduction. J. Clin. Oncol: Classic papers and current comments: highlights of lung cancer research 6, 1-3 (2001).
27. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. update. J. Clin. Oncol: Classic papers and current comments: highlights of lung cancer research 6, 87-96 (2001).
28. Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin P. An economic analysis of the TAX 317 trial, docetaxel versus best supportive care as second-line therapy of advanced non-small cell lung cancer. J. Clin. Oncol. 20, 1344-1352 (2002).